B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. The annualized relapse rate was lower with ocrelizumab ...
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an α 4 integrin antagonist, appeared to be safe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback